Clinical Trials Sponsored by MedDay Pharmaceuticals SA

Total 70 results

MedDay Pharmaceuticals SA

Terminated

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) (SPI2)

Multiple Sclerosis

United States, Spain, Canada, Australia, United Kingdom, Belgium, Turkey, Czechia, Poland, Italy, Hungary, Germany, Sweden
MedDay Pharmaceuticals SA

Completed

MD1003-AMN MD1003 in Adrenomyeloneuropathy

Adrenoleukodystrophy | Adrenomyeloneuropathy | AMN

France, Germany, Spain
MedDay Pharmaceuticals SA

Completed

Effect of MD1003 in Amyotrophic Lateral Sclerosis (MD1003-ALS)

Motor Neuron Disease | Amyotrophic Lateral Sclerosis | ALS

France
MedDay Pharmaceuticals SA

Completed

SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

Charcot-Marie-Tooth Disease | Peripheral Neuropathy | Chronic Inflammatory Demyelinating Polyneuropathy | Charcot-Marie-Tooth Disease Type 1A | Charcot-Marie-Tooth Disease, Type 1B | Anti-MAG Neuropathy

France
MedDay Pharmaceuticals SA

Unknown

Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis (MS-ON)

Multiple Sclerosis

United Kingdom, France
MedDay Pharmaceuticals SA

Unknown

Effect of MD1003 in Spinal Progressive Multiple Sclerosis (MS-SPI)

Multiple Sclerosis

France
MedDay Pharmaceuticals SA
Eurofins Optimed

Terminated

RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects

Healthy Volunteers | Impaired Renal Function

France, Hungary
MedDay Pharmaceuticals SA
Quotient Sciences

Completed

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects

Healthy Volunteers

United Kingdom
MedDay Pharmaceuticals SA
Eurofins Optimed

Terminated

HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects

Healthy Volunteers | Hepatic Impairment of Moderate Child Pugh Category

France, Hungary
MedDay Pharmaceuticals SA
Parexel; ERT: Clinical Trial Technology Solutions

Unknown

TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects (TQT2)

Healthy Volunteers

United Kingdom
Hospital do Coracao
Medley Pharmaceutical Industry SA

Completed

The Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT)

Acute Kidney Failure

Brazil
Rhizen Pharmaceuticals SA

Completed

Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

Georgia, Bulgaria, Poland
Rhizen Pharmaceuticals SA

Terminated

Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

Classical Hodgkin Lymphoma

United States
Rhizen Pharmaceuticals SA

Terminated

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

Lymphoma

United States, Australia
Rhizen Pharmaceuticals SA

Completed

To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers

Healthy

Canada
Fovea Pharmaceuticals SA

Completed

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Fovea Pharmaceuticals SA

Terminated

Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion (FOV2302)

Central Retinal Vein Occlusion | Macular Edema

France
Rhizen Pharmaceuticals SA

Active, not recruiting

Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors

Solid Tumor | Metastatic Breast Cancer | Locally Advanced Breast Cancer | Extensive-stage Small-cell Lung Cancer | Platinum-Sensitive Fallopian Tube Carcinoma | Platinum-sensitive Ovarian Cancer | Platinum-Sensitive Peritoneal Cancer

Czechia, Poland
Rhizen Pharmaceuticals SA

Completed

Compassionate Use Study of Tenalisib (RP6530)

Hematological Malignancies

United States, Georgia, Poland
Rhizen Pharmaceuticals SA

Completed

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

T Cell Lymphoma

United States
Rhizen Pharmaceuticals SA

Completed

A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects

Healthy Volunteers

United States
Rhizen Pharmaceuticals SA

Completed

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral

United States
Rhizen Pharmaceuticals SA

Completed

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies (PI3K)

Lymphoma, B-Cell | T-Cell Lymphoma

France, Italy
Rhizen Pharmaceuticals SA

Completed

Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Georgia
Rhizen Pharmaceuticals SA

Withdrawn

Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia
Rhizen Pharmaceuticals SA

Withdrawn

Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

Peripheral T Cell Lymphoma

United States
Rhizen Pharmaceuticals SA

Completed

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

Non Hodgkin Lymphoma

United States, Australia
Rhizen Pharmaceuticals SA

Terminated

Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals

Asthma | Healthy Volunteers

Canada
Fovea Pharmaceuticals SA

Completed

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

Diabetic Macular Edema

United States, Australia, Belgium, Czech Republic, France, Germany, Israel, Italy, Poland, Spain
Fovea Pharmaceuticals SA

Completed

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

Allergic Conjunctivitis

United States
Meda Pharmaceuticals

Completed

A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis

Perennial Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Seasonal Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Seasonal Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis

Perennial Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

Perennial Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Seasonal Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back

Lower Back Pain

United States
Meda Pharmaceuticals

Completed

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Seasonal Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back

Lower Back Pain

United States
Meda Pharmaceuticals

Completed

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies

Seasonal Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

Seasonal Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

Seasonal Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis

Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Seasonal Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Seasonal Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Seasonal Allergic Rhinitis

United States
Meda Pharmaceuticals

Completed

Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis

Chronic Allergic Rhinitis | Nonallergic Rhinitis

United States
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Completed

To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Completed

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Terminated

Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers (GBR 1302-101)

HER2 Expressing Solid Tumours

United States, Germany

3

Subscribe